QC
ENGN icon

Quadrature Capital’s enGene Therapeutics ENGN Stock Holding History

Quadrature Capital’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$230K Sell
33,797
-14,786
-30% -$132K ﹤0.01% 1070
2025
Q4 		$439K Buy
+48,583
New +$389K ﹤0.01% 729

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Quadrature Capital's ENGN Position: Q1 2026 in Review

Quadrature Capital reduced its enGene Therapeutics (ENGN) stake by 30% in Q1 2026, selling an estimated $132K and leaving 33,797 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1070.

Quadrature Capital first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $439K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Quadrature Capital held 33,797 shares of enGene Therapeutics worth $230K as of Q1 2026.
  • Quadrature Capital sold 14,786 enGene Therapeutics shares in Q1 2026, an estimated $132K.
  • enGene Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q1 2026, its #1070 holding.
  • Quadrature Capital first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's enGene Therapeutics position peaked at $439K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.